1. Home
  2. NICE vs ABVX Comparison

NICE vs ABVX Comparison

Compare NICE & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NICE Ltd

NICE

NICE Ltd

HOLD

Current Price

$106.25

Market Cap

8.6B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$110.98

Market Cap

9.6B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NICE
ABVX
Founded
1986
2013
Country
Israel
France
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.6B
9.6B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
NICE
ABVX
Price
$106.25
$110.98
Analyst Decision
Buy
Strong Buy
Analyst Count
13
12
Target Price
$168.46
$112.83
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
11-13-2025
08-11-2025
Dividend Yield
N/A
N/A
EPS Growth
35.79
N/A
EPS
8.79
N/A
Revenue
$2,880,503,000.00
$7,073,400.00
Revenue This Year
$9.20
$6.80
Revenue Next Year
$6.96
N/A
P/E Ratio
$12.39
N/A
Revenue Growth
9.24
N/A
52 Week Low
$99.00
$4.77
52 Week High
$193.52
$130.25

Technical Indicators

Market Signals
Indicator
NICE
ABVX
Relative Strength Index (RSI) 35.97 50.41
Support Level $104.13 $114.06
Resistance Level $109.24 $130.25
Average True Range (ATR) 5.60 6.53
MACD -0.05 -1.06
Stochastic Oscillator 19.19 35.29

Price Performance

Historical Comparison
NICE
ABVX

About NICE NICE Ltd

NICE Ltd is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: